5-tert-butyl-pyridine-2-carboxylic acid {2-methyl-3-[5-(6-morpholin-4-yl-pyridazin-3-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-phenyl}-amide | 1013116-78-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-tert-butyl-pyridine-2-carboxylic acid {2-methyl-3-[5-(6-morpholin-4-yl-pyridazin-3-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-phenyl}-amide
• 英文别名: 5-tert-Butyl-N-(2-methyl-3-(5-(6-morpholinopyridazin-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)picolinamide；5-tert-butyl-N-[2-methyl-3-[5-[(6-morpholin-4-ylpyridazin-3-yl)amino]-6-oxo-1H-pyridin-3-yl]phenyl]pyridine-2-carboxamide
• CAS: 1013116-78-3
• 化学式: C₃₀H₃₃N₇O₃
• 分子量: 539.637
• InChiKey: CTNLNMHAOFPTEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  40
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Certain Substituted Amides, Method of Making, and Method of Use Thereof
  申请人：Blomgren Peter A.

  公开号：US20080153834A1

  公开（公告）日：2008-06-26

  At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了至少选择自化合物Formula 1和药用可接受盐、溶剂化合物、螯合物、非共价复合物、前药和它们的混合物中的至少一种化学实体。本发明的药物组合物包括至少一种化学实体，以及至少选择自载体、佐剂和辅料的药用可接受载体。描述了用于治疗对Btk活性和/或B细胞活性抑制敏感的某些疾病的患者的方法。描述了用于确定样本中Btk存在的方法。
• SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP2079726A2

  公开（公告）日：2009-07-22
• US7838523B2
  申请人：——

  公开号：US7838523B2

  公开（公告）日：2010-11-23
• [EN] CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF<br/>[FR] AMIDES SUBSTITUÉS, PROCÉDÉ DE PRODUCTION ET D'UTILISATION DESDITS AMIDES
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2008033857A2

  公开（公告）日：2008-03-20

  [EN] At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
  [FR] La présente invention concerne au moins une entité chimique choisie parmi des composés de formule (1) et des sels, des solvates, des chélates, des complexes non-covalents, des pro-médicaments de qualité pharmaceutique, et des mélanges de ces substances. Elle concerne également des compositions pharmaceutiques comportant au moins une entité chimique selon l'invention, ainsi qu'un véhicule de qualité pharmaceutique choisi parmi des adjuvants transporteurs et des excipients. Des méthodes de traitement de patients souffrant de certaines maladies répondant à l'inhibition de l'activité Btk et / ou de l'activité des lymphocytes B, ainsi que des méthodes de détermination de la présence de Btk dans un échantillon sont également décrites.